AtaCor Medical announced today that it entered a financing worth up to $75 million to support its U.S. FDA pivotal study.

AtaCor Medical, Inc., a privately-held medical device company focused on transforming cardiac rhythm management systems, ...

One of the timeliest and, some say controversial, topics in clinical cardiac electrophysiology today is the proper role of the implantable cardioverter-defibrillator (ICD) in the treatment of patients ...

On top of performing implantable cardioverter-defibrillator (ICD) functions, the integrated device also delivered appropriate ...

Please provide your email address to receive an email when new articles are posted on . Abbott announced that a cardiac resynchronization therapy defibrillator and an implantable cardioverter ...

Background: Although more than 150,000 implantable cardioverter defibrillators (ICDs) are implanted yearly worldwide, only few studies systematically examined complications of ICD therapy in large ...

A standard test of the implantable cardioverter defibrillator (ICD) is linked to significant thought-processing problems that improve for most patients within a year after the device is inserted, ...

A wearable automatic defibrillator may be an alternative to an implantable cardiac defibrillator for a small group of patients, say researchers. There are few large, randomized and controlled clinical ...

Background Sudden cardiac death (SCD) is a common cause of cardiovascular mortality, often triggered by ventricular ...